Transcranial Direct Current Stimulation to Enhance Training Effectiveness in Chronic Post-Stroke Aphasia
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Agnes Floeel, Prof.
- Phone Number: +49 3834 86 6815
- Email: agnes.floeel@uni-greifswald.de
Study Contact Backup
- Name: Nina Unger
- Phone Number: +49 3834 86 6749
- Email: nina.unger@uni-greifswald.de
Study Locations
-
-
-
Aachen, Germany, 52074
- Aphasiestation RWTH Aachen
-
Allensbach, Germany, 78476
- Kliniken Schmieder Allensbach
-
Bad Aibling, Germany, 83209
- Schön Klinik Bad Aibling Harthausen
-
Bad Homburg, Germany, 61348
- Wicker Klinik Bad Homburg
-
Bad Klosterlausnitz, Germany, 07639
- Moritz Kliniken Bad Klosterlausnitz
-
Bad Sülze, Germany, 18334
- Median Klinik Bad Sülze
-
Berlin, Germany, 10115
- ZAR Berlin
-
Gailingen, Germany, 78262
- Kliniken Schmieder Gailingen
-
Greifswald, Germany, 17475
- University Medicine Greifswald, Department of Neurology
-
Greifswald, Germany, 17491
- BDH-Klinik Greifswald gGmbH
-
Göppingen, Germany, 73035
- Klinikum Christophsbad Göppingen
-
Heidelberg, Germany, 69117
- Kliniken Schmieder Heidelberg
-
Kempen, Germany, 47906
- Hospital zum Heiligen Geist Kempen
-
Leipzig, Germany, 04103
- Tagesklinik MPI Leipzig
-
Lindlar, Germany, 51789
- Logo Zentrum Lindlar
-
Marbach, Germany, 71672
- TheraVent aktiv Marbach
-
Meerbusch, Germany, 40670
- St. Mauritius Therapieklinik
-
Rostock, Germany, 18057
- EUFH Rostock
-
Vechta, Germany, 49377
- Aphasie-Zentrum Vechta gGmbH
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- left-hemisphere cortical or subcortical stroke with first-ever aphasic symptoms
- at least 6 months post-onset of stroke;
- aphasia, as determined by the Aachen Aphasia Test (AAT);
- 13 moderate-to-severe word finding difficulties (maximum of 75% correct items on a computerized naming task at baseline);
- at least 1 correct reaction on the first part of the AAT subscale Token Test (ensuring basic comprehension skills);
- at least 1 point on the communicative task of the AAT subscale Spontaneous Speech (ensuring basic communication abilities);
- German as first language;
- intact left-hemisphere "hand knob" without right prefrontal lesions for placement of tDCS electrodes, as confirmed by magnetic resonance imaging or computer tomography scans.
Exclusion Criteria:
- contraindications for tDCS (e.g., cardiac pacemaker, history of seizures, implanted metal inside the head);
- more than one clinically apparent stroke with aphasic symptoms;
- other severe neurological diseases (e.g., brain tumor, and subdural hematoma);
- epilepsy with seizures during the last 12 months prior to study start and/or intake of sedating antiepileptic drugs (barbiturates and benzodiazepines),
- history of severe alcohol or drug abuse;
- current severe depression;
- current psychosis or other relevant psychiatric condition;
- very severe apraxia of speech, as revealed by Hierarchical Word Lists;
- severe non-verbal cognitive deficits, as indicated by the Corsi Block-Tapping Task;
- severe uncontrolled medical problems;
- severely impaired vision or hearing that prevents patients from engaging in intensive SLT;
- changes in centrally active drugs within 2 weeks prior to study inclusion.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Experimental group
Anodal transcranial direct current stimulation (tDCS) combined with speech-language therapy (SLT, including naming therapy and communicative-pragmatic therapy)
|
Two daily sessions of intensive SLT combined with tDCS of the left primary motor cortex (M1)
|
|
Sham Comparator: Control group
Placebo stimulation (using sham-tDCS) combined with SLT
|
Two daily sessions of intensive SLT combined with tDCS of the left primary motor cortex (M1)
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in communication ability, as assessed by the Amsterdam Nijmegen Everyday Language Test
Time Frame: Before the 3-week treatment period; immediately after the 3-week treatment period; 6- and 12-month follow ups
|
Amsterdam Nijmegen Everyday Language Test (A-scale; parallel versions used in counterbalanced order across participants); cf.
Blomert L, Kean ML, Koster C, et al.
Amsterdam-Nijmegen Everyday Language Test-Construction, Reliability and Validity.
Aphasiology 1994; 8: 381-407.
|
Before the 3-week treatment period; immediately after the 3-week treatment period; 6- and 12-month follow ups
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in naming ability, as assessed based on personally relevant trained and untrained items, consistent with previous work (see description)
Time Frame: Before the 3-week treatment period; immediately after the 3-week treatment period; 6- and 12-month follow ups
|
Personally relevant trained and untrained items, consistent with previous work; cf.
Meinzer M, Darkow R, Lindenberg R, et al.
Electrical stimulation of the motor cortex enhances treatment outcome in post-stroke aphasia.
Brain 2016; 139: 1152-1163.
|
Before the 3-week treatment period; immediately after the 3-week treatment period; 6- and 12-month follow ups
|
|
Change in (non-)verbal communication, as assessed by the Scenario Test
Time Frame: Before the 3-week treatment period; 6-month follow-up
|
Scenario Test; cf.
Nobis-Bosch R, Abel S, Krzok F, et al.
Szenario Test-Testung verbaler und nonverbaler Aspekte aphasischer Kommunikation.
ProLog, in preparation.
|
Before the 3-week treatment period; 6-month follow-up
|
|
Change in (non-)verbal communication, as assessed by the Communicative Effectiveness Index
Time Frame: Before the 3-week treatment period; immediately after the 3-week treatment period; 6- and 12-month follow ups
|
Communicative Effectiveness Index; cf.
Lomas J, Pickard L, Bester S, et al.
The Communicative Effectiveness Index: development and psychometric evaluation of a functional communication measure for adult aphasia.
J Speech Hear Disord 1989; 54: 113-124.
|
Before the 3-week treatment period; immediately after the 3-week treatment period; 6- and 12-month follow ups
|
|
Change in attention and executive function, as assessed by the subscales Go/NoGo and Alertness from Test of Attentional Performance
Time Frame: Before the 3-week treatment period; 6-month follow up
|
Subscales Go/NoGo and Alertness from Test of Attentional Performance; cf.
Zimmermann P and Fimm B. Testbatterie zur Aufmerksamkeitsprüfung (TAP).
Herzogenrath: PSYTEST Verlag, 2002.
|
Before the 3-week treatment period; 6-month follow up
|
|
Change in non-verbal episodic memory, as assessed by the Figure Recognition Task from Benton Visual Retention Test
Time Frame: Before the 3-week treatment period; 6-month follow up
|
Figure Recognition Task from Benton Visual Retention Test; cf.
Benton Sivan A and Spreen O. Benton Test.
Bern: Huber, 2009.
|
Before the 3-week treatment period; 6-month follow up
|
|
Change in mood, as assessed by the German version of the 10-item Stroke Aphasic Depression Questionnaire
Time Frame: Before the 3-week treatment period; immediately after the 3-week treatment period; 6- and 12-month follow ups
|
German version of the 10-item Stroke Aphasic Depression Questionnaire (SADQH-10); cf.
Cobley CS, Thomas SA, Lincoln NB, et al.
The assessment of low mood in stroke patients with aphasia: reliability and validity of the 10-item Hospital version of the Stroke Aphasic Depression Questionnaire (SADQH-10).
Clin Rehabil 2012; 26: 372-381.
|
Before the 3-week treatment period; immediately after the 3-week treatment period; 6- and 12-month follow ups
|
|
Change in health-related quality of life, as assessed by the Stroke and Aphasia Quality of Life Scale
Time Frame: Before the 3-week treatment period; immediately after the 3-week treatment period; 6- and 12-month follow ups
|
Stroke and Aphasia Quality of Life Scale (SAQOL-39g); cf.
Hilari K, Lamping DL, Smith SC, et al.
Psychometric properties of the Stroke and Aphasia Quality of Life Scale (SAQOL-39) in a generic stroke population.
Clin Rehabil 2009; 23: 544-557.
|
Before the 3-week treatment period; immediately after the 3-week treatment period; 6- and 12-month follow ups
|
|
Change in health-related quality of life, as assessed by the EuroQol Health-Related Quality of Life Questionnaire
Time Frame: Before the 3-week treatment period; immediately after the 3-week treatment period; 6- and 12-month follow ups
|
EuroQol Health-Related Quality of Life Questionnaire (EQ-5D-5L); cf.
EuroQol G. EuroQol-a new facility for the measurement of health-related quality of life.
Health Policy 1990; 16: 199-208.
|
Before the 3-week treatment period; immediately after the 3-week treatment period; 6- and 12-month follow ups
|
|
Change in direct and indirect costs during the 12-month study period, as assessed by the self-developed Patient Resource Consumption Questionnaire
Time Frame: Before the 3-week treatment period; 6- and 12-month follow ups
|
Direct and indirect costs during the 12-month study period, as determined by the self-developed Patient Resource Consumption Questionnaire considering common standardized unit cost assumptions.
|
Before the 3-week treatment period; 6- and 12-month follow ups
|
|
Change in direct and indirect costs during the 12-month study period, as assessed by the Quality-Adjusted Life Years
Time Frame: Before the 3-week treatment period; 6- and 12-month follow ups
|
Quality-Adjusted Life Years; cf.
Whitehead SJ and Ali S. Health outcomes in economic evaluation: the QALY and utilities.
Br Med Bull 2010; 96: 5-21.
|
Before the 3-week treatment period; 6- and 12-month follow ups
|
|
Change in unpaid support provided by family members or friends, as assessed by the Burden of informal caregivers
Time Frame: Before the 3-week treatment period; immediately after the 3-week treatment period; 6- and 12-month follow ups
|
Burden of informal caregivers; cf.
van Exel NJ, Koopmanschap MA, van den Berg B, et al.
Burden of informal caregiving for stroke patients.
Identification of caregivers at risk of adverse health effects.
Cerebrovasc Dis 2005; 19: 11-17.
|
Before the 3-week treatment period; immediately after the 3-week treatment period; 6- and 12-month follow ups
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Agnes Floeel, Prof., University Medicine Greifswald
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- DC-Train-Aphasia
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.